The Medicines and Healthcare products Regulatory Agency has approved an "adapted" version of the Comirnaty Covid vaccination for adults.

The Pfizer/BioNTech Comirnaty KP.2 Covid vaccine, which triggers the production of antibodies and blood cells by the immune system to work against the virus, was given the green light by the medicines regulator yesterday. 

The MHRA said it approved two “presentations of the adapted Comirnaty KP.2 Covid vaccine” having found they met its “standards of safety, quality, and effectiveness.”

The two products are Comirnaty KP.2 30 micrograms/dose dispersion for injection in multidose vials for use in adults and Comirnaty KP.2 30 micrograms/dose dispersion for injection in pre-filled syringe for use in adults.

The MHRA said it will “keep the safety of the vaccine under close review” and urged anyone experiencing any side effects to talk to their doctor, pharmacist or nurse.